Safety and Immunogenicity Study of a H5N1 Influenza Vaccine (Vero Cell-Derived, Whole Virus) in Healthy Infants, Children and Adolescents

Phase 1

Completed

• Conditions: Influenza, Avian

• Registration Number: NCT01052402
• Lead Sponsor: Resilience Government Services, Inc.

Brief Summary

The purpose of this study is to assess the safety and immunogenicity (i.e. primary immune response, immunogenicity of two different doses, antibody persistence 360 days after the first vaccination, immune response to a heterologous booster given on Day 360) of a Vero cell-derived whole virus H5N1 influenza vaccine in healthy infants, children and adolescents aged 6 months to 17 years.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-12
• Study First Submitted: 2010-01-18
• Study First Submitted QC: 2010-01-19
• Study First Posted: 2010-01-20
• Primary Completion: 2011-11
• Status Verified: 2012-11
• Study Completion: 2012-11
• Last Update Submitted: 2015-10-07
• Last Update Posted: 2015-10-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 684

Inclusion Criteria

• 9 to 17 years of age on the day of screening (for Stratum A only)
• 3 to 8 years of age on the day of screening (for Stratum B only)
• 6 to 35 months of age on the day of screening (for Stratum C only)
• Subject who were born at full term of pregnancy (>= 37 weeks) with a birth weight >= 2 kg (for Stratum C only)
• Subjects and/or their parents/legal guardians understand the nature and procedures of the study and agree to its provisions
• Subjects´ parents/legal guardians provide written consent for participation according to national law. In case the parents/legal guardians are illiterate, the informed consent is also to be signed by an independent witness
• Written assent according to subjects´ age and capacity of understanding
• Subjects who are generally healthy, as determined by the investigator's clinical judgment through collection of medical history and performance of a physical examination
• Subjects who are physically and mentally capable of participating in the study and follow its procedures
• Subjects and/or their parents/legal guardians agree to keep a daily record of symptoms for the duration of the study
• If subjects are female of childbearing potential - have a negative urine pregnancy test result within 24 hours prior to the scheduled first vaccination and agree to employ adequate birth control measures for the duration of the study

Exclusion Criteria

• History of exposure to H5N1 virus or a history of vaccination with an H5N1 influenza vaccine
• High risk of contracting H5N1 influenza infection (e.g. contact with poultry);
• Subjects who currently have or have a history of a significant neurological, cardiovascular, pulmonary (including asthma), hepatic, metabolic, rheumatic, autoimmune, hematological or renal disorder
• Inherited or acquired immunodeficiency
• Subjects who have a disease or are currently undergoing a form of treatment or were undergoing a form of treatment within 30 days prior to study entry that can be expected to influence immune response. Such treatment includes, but is not limited to, systemic or high dose inhaled corticosteroids, radiation treatment or other immunosuppressive or cytotoxic drugs.
• History of severe allergic reactions or anaphylaxis
• Rash, dermatological condition or tattoos which may interfere with injection site reaction rating
• Subjects who have received a blood transfusion or immunoglobulins within 90 days prior to study entry
• Subjects who have received any live vaccine within 4 weeks or inactivated vaccine within 2 weeks prior to vaccination in this study
• Functional or surgical asplenia
• Subjects with a known or suspected problem with alcohol or drug abuse
• Subjects who were administered an investigational drug within six weeks prior to study entry or are concurrently participating in a clinical study that includes the administration of an investigational product
• Dependent relationship with the study site personnel. Dependent relationships include close relatives (i.e., children, siblings).
• If female: subjects wo are pregnant or lactating

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Frequency and severity of systemic reactions until 7 days after the first vaccination	7 days
Rate of subjects with antibody response to the vaccine strain associated with protection 21 days after the second vaccination defined as titer measured by Microneutralization test >= 1:20.	42 days

Secondary Outcome Measures

Name	Time	Method
Frequency and severity of systemic and injection site reactions until 21 days after the first, second and booster vaccination	Day 21, 42 and 381
Fever, malaise or shivering (in children and adolescents aged 3 to 17 years) and fever and irritability (in infants and young children aged 6 to 35 months) with onset within 7 days after the first, second and booster vaccination	Day 21, 42 and 381
Adverse events observed during the entire study period	Throughout entire study period
Antibody response associated with protection 21 days after the first and second vaccination, and again at 360 days after the first vaccination and 21 days after the booster vaccination	Day 21, 42, 360 and 381	Antibody response defined as Hemagglutination Inhibition Antibody (HIA) titer \>= 1:40 or Single Radial Hemolysis (SRH) area \>= 25 mm2, and as measured by Microneutralization (MN) test \>= 1:20
Fold increase of antibody response 21 days after first and second vaccination as compared to baseline, and again at 21 days after the booster vaccination as compared to before the booster vaccination	Day 21, 42, 360 and 381	Measured by MN, HI and SRH assay
Seroconversion 21 days after the first and second vaccination and at 21 days after the booster vaccination	Day 21, 42 and 381	Measured by MN, HI and SRH assay

Trial Locations

Locations (20)

Princess Margaret Hospital for Children; 🇦🇺 Subiaco, Australia

Tampere University, Espoo Vaccine Research (Tampereen Yliopisto, Espoon Rokotetutkimus); 🇫🇮 Espoo, Finland

South Helsinki Vaccine Research Clinic (Etelä-Helsingin Rokotetutkimusklinikka); 🇫🇮 Helsinki, Finland

Kokkola Vaccine Research Clinic (Kokkolan Rokotetutkimusklinikka); 🇫🇮 Kokkola, Finland

Kuopion Vaccine Research Clinic; 🇫🇮 Kuopio, Finland

Oulu Vacine Research Clinic (Oulun Rokotetutkimusklinikka); 🇫🇮 Oulu, Finland

Porin Vaccine Research Clinic; 🇫🇮 Pori, Finland

University of Tampere, Seinäjoki Vaccine Research Clinic (Tampereen Yliopisto, Seinajoen Rokotetutkimusklinikka); 🇫🇮 Seinäjoki, Finland

Tampere Vacine Research Clinic (Tampereen Rokotetutkimusklinikka); 🇫🇮 Tampere, Finland

Turku Vaccine Research Clinic (Turun Rokotetutkimusklinikka); 🇫🇮 Turku, Finland

Scroll for more (10 remaining)